Kobe University · Research Center for Urban Safety and Security · 准教授

Research keywordsB cell receptor repertoire・antibody language models・mRNA vaccine immunogenicity・urinary Gram stain classification・HIV treatment satisfaction・vertebral osteomyelitis・COVID 19 clonal B cells・allogeneic stem cell transplantation

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Tuberculosis with Multiserosal Dissemination.2026 · 2026年02月, Internal medicine (Tokyo, Japan), 英語, 国内誌
• LM-QASAS: Reference-free identification of antigen-specific sequences from the BCR repertoire using antibody language models2026 · 2026年04月
• 2025 ICM: Samples for Culture.2025 · 2025年12月, The Journal of arthroplasty, 41(1S1) (1S1), S277-S284, 英語, 国際誌
• Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d)2024 · A monovalent Omicron XBB.1.5 mRNA RBD analogue vaccine, MAFB-7256a (DS-5670d), was newly developed and approved in Japan in the Spring of 2024 for the prevention of COVID-19. However, clinical efficacy data for this vaccine are currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assays and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of MAFB-7256a. We analyzed repeated blood samples using the QASAS method from three healthy volunteers before and after MAFB-7256a vaccination. BCR response increased rapidly one week post-vaccination and then decreased, as with conventional vaccine. Notably, the matched sequences after MAFB-7256a vaccination specifically bound to the receptor-binding domain (RBD), with no sequences binding to other epitopes. These results validate that MAFB-7256a is an effective vaccine that exclusively induces antibodies specific for the RBD, demonstrating its targeted immunogenic effect.

• 感染症およびワクチン接種による免疫反応の網羅的評価法 大路 剛 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2026年04月01日 - 2029年03月31日2026 · KUID parsed section
• 細菌感染症菌種推定支援AI医療機器の経済効果に関する研究 国立研究開発法人日本医療研究開発機構, 令和6年度 「デジタルヘルスケア開発・導入加速化事業」, 2025年07月 - 2026年03月2025 · KUID parsed section
• 細菌の自動培養モニタリングシステムによる細菌有無判定精度評価 大路 剛, 大沼健一郎 2023年05月 - 2025年03月, 研究代表者2023 · KUID parsed section
• 「簡易自動グラム染色機械」の開発 大路 剛, 大沼 健一郎, 楠木 まり カーブジェン株式会社, 2022年07月 - 2022年12月, 連携研究者2022 · KUID parsed section

• Official profile